NCT02724904View on ClinicalTrials.gov

Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2017

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2021

Conditions
Lymphoma
Interventions
PROCEDURE

Allogeneic stem cell transplantation

Reduced intensity allogeneic stem cell transplantation from a fully matched related or unrelated donor

DRUG

Fludarabine

Standard Treatment

DRUG

Thiotepa

Standard Treatment

DRUG

Methotrexate

IV Bolus

Trial Locations (2)

02115

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Adienne SA
All Listed Sponsors
collaborator

Adienne SA

INDUSTRY

collaborator

Dana-Farber Cancer Institute

OTHER

lead

Massachusetts General Hospital

OTHER